Securing America’s Drug Supply from Communist China Act

The bill titled "A bill to require regulatory review of pharmaceutical products from Chinese entities, and for other purposes," was introduced in the 119th Congress on April 16, 2026. The bill aims to mandate regulatory review processes specifically for pharmaceutical products originating from Chinese entities, likely focusing on ensuring safety, efficacy, and compliance standards for such products.